Mounjaro contains tirzepatide. The medicine is used in different clinical settings, but diabetes care and weight management are not the same task. This guide helps separate product information from headlines. It is based on European information checked on 16 October 2026.
Separate the two treatment indications
EU authorisation includes inadequately controlled type 2 diabetes in adults and in children and adolescents from age ten. The weight-management indication is for adults. Its initial BMI criteria are at least 30, or at least 27 with a weight-related condition, alongside dietary measures and physical activity.
This does not mean everyone within a BMI category should receive Mounjaro. A clinician considers the whole situation. Equally, the diabetes indication from age ten must not be turned into a claim that the product is generally authorised for weight loss in children.
What the dual mechanism explains
Tirzepatide activates receptors for two natural signalling hormones, GIP and GLP-1. Its actions include effects on food-related insulin secretion and appetite. “Dual” describes the receptors involved; it does not guarantee twice the benefit.
The change you hope for should match your clinical goals. Diabetes appointments involve different measurements and accompanying treatments from weight-management appointments alone. Ask how benefit and tolerability will be assessed rather than concentrating only on the largest weight reduction mentioned online.
Read comparisons beyond the headline
Direct comparison trials can be informative, but they involve specified participants, periods and treatment regimens. SURMOUNT-5 compared tirzepatide with injectable semaglutide in adults with obesity without type 2 diabetes. Its findings do not compare every tablet or every regimen available today.
Also ask whether a headline is describing weight, blood glucose or cardiovascular events. Greater weight loss in a particular trial does not establish the greatest overall health benefit for every individual. Whenever numbers are quoted, read the population, duration and comparison alongside them.
Information your clinician needs
Prepare a complete medicines list, previous intolerances and existing conditions. Mention significant digestive symptoms, previous pancreatic problems and planned procedures in particular. If you use insulin or certain other diabetes medicines, the team also needs to consider low blood glucose risk.
Pregnancy plans, pregnancy and breastfeeding need separate discussions. Current EU information does not recommend tirzepatide during pregnancy. Breastfeeding requires an individual clinical assessment. Blanket statements about all GLP-1 medicines, or instructions copied from another regulatory region, can be misleading here.
Arrange practical support before starting
Mounjaro is injected. Follow the information belonging to the exact presentation prescribed for administration and storage. Ask a clinician or pharmacist to clarify uncertainties. Do not borrow instructions for another pen or calculate clicks and product switches yourself.
Agree when to report changes and who will be available. Digestive adverse effects deserve attention, particularly if eating or drinking is affected. Persistent severe abdominal pain or signs of a severe allergic reaction need immediate medical assessment. Discuss follow-up appointments, ongoing costs and possible supply problems before they create pressure to make hurried decisions.
Common questions
Is Mounjaro a form of insulin?
No. Tirzepatide is a different substance. If you need insulin, do not replace it with Mounjaro or alter it yourself. Your clinician must oversee the overall diabetes treatment.
Does a new study mean a new approved indication?
No. Study findings can be added to product information without creating a separate indication. Check the current authorised-use section and the country to which the information applies.
Sources & further reading
- EMA: Mounjaro – EPAR und Produktinformation
- SURMOUNT-5: Tirzepatide compared with semaglutide, 2025
- WHO: GLP-1 therapies for obesity, 1 December 2025
Sources checked:
Questions and experiences
Share a question or a useful experience about this topic. Every contribution is checked before publication. Comments may be written in different languages.
Loading reader contributions…
Opening the form sets a necessary session cookie. No email address is required. Publication is subject to moderation and is not guaranteed. For deletion requests: Contact